Why some patients respond poorly to statins and how this might be remedied

被引：48

作者：

Thompson, GR

O'Neill, F

Seed, M

机构：

[1] Hammersmith Hosp, Imperial Coll Sch Med, Dept Invest Sci, London W12 0NN, England

[2] Hammersmith Hosp, Imperial Coll Sch Med, Dept Med, London W12 0NN, England

[3] Charing Cross Hosp, Imperial Coll Sch Med, Dept Invest Sci, London W6 8RP, England

[4] Charing Cross Hosp, Imperial Coll Sch Med, Dept Med, London W6 8RP, England

来源：

EUROPEAN HEART JOURNAL | 2002年 / 23卷 / 03期

关键词：

cholesterol; cholestanol; campesterol; hyper-responder; hypo-responder; statin;

D O I：

10.1053/euhj.2001.3071

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：200 / 206

页数：7

共 46 条

[1] Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy [J].

Ballantyne, CM ;

Herd, JA ;

Stein, EA ;

Ferlic, LL ;

Dunn, JK ;

Gotto, AM ;

Marian, AJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (05) :1572-1578

[2]

BAYS H, 2000, ATHEROSCLEROSIS, V151, P135

[3] Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters [J].

Berge, KE ;

Tian, H ;

Graf, GA ;

Yu, LQ ;

Grishin, NV ;

Schultz, J ;

Kwiterovich, P ;

Shan, B ;

Barnes, R ;

Hobbs, HH .

SCIENCE, 2000, 290 (5497) :1771-1775

[4]

Berger GMB, 1998, J LIPID RES, V39, P1046

[5] APOLIPOPROTEIN-E PHENOTYPES IN FAMILIAL HYPERCHOLESTEROLEMIA - IMPORTANCE FOR EXPRESSION OF DISEASE AND RESPONSE TO THERAPY [J].

BERGLUND, L ;

WIKLUND, O ;

EGGERTSEN, G ;

OLOFSSON, SO ;

ERIKSSON, M ;

LINDEN, T ;

BONDJERS, G ;

ANGELIN, B .

JOURNAL OF INTERNAL MEDICINE, 1993, 233 (02) :173-178

[6] Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy [J].

Blair, SN ;

Capuzzi, DM ;

Gottlieb, SO ;

Nguyen, T ;

Morgan, JM ;

Cater, NB .

AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (01) :46-52

[7] Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors -: The role of metabolism -: Monograph for physicians [J].

Bottorff, M .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (15) :2273-2280

[8] THE RESPONSE TO LOVASTATIN TREATMENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IS MODULATED BY APOLIPOPROTEIN-E POLYMORPHISM [J].

CARMENA, R ;

ROEDERER, G ;

MAILLOUX, H ;

LUSSIERCACAN, S ;

DAVIGNON, J .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (07) :895-901

[9]

CHISHOLM A, 1992, Q J MED, V85, P825

[10] LOVASTATIN EFFICACY IN REDUCING LOW-DENSITY-LIPOPROTEIN CHOLESTEROL LEVELS ON HIGH-FAT VS LOW-FAT DIETS [J].

COBB, MM ;

TEITELBAUM, HS ;

BRESLOW, JL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (08) :997-1001

← 1 2 3 4 5 →